ID

37227

Description

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT02071862

Link

https://clinicaltrials.gov/show/NCT02071862

Keywords

  1. 7/9/19 7/9/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 9, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Solid Tumors NCT02071862

Eligibility Solid Tumors NCT02071862

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. newly diagnosed patients who refuse standard treatment regimens are also eligible
Description

Malignant Neoplasms Advanced Recurrent | Malignant Neoplasms Advanced Unresponsive to Treatment | Therapy All Benefit | Patients Standard therapy Refused

Data type

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C0277556
UMLS CUI [2,1]
C0006826
UMLS CUI [2,2]
C0205179
UMLS CUI [2,3]
C0205269
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0444868
UMLS CUI [3,3]
C0814225
UMLS CUI [4,1]
C0030705
UMLS CUI [4,2]
C2936643
UMLS CUI [4,3]
C1705116
eastern cooperative oncology group (ecog) performance status of 0-1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of at least 3 months
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
adequate hepatic, renal, cardiac, and hematologic function
Description

Liver function | Renal function | Cardiac function | Hematologic function

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232164
UMLS CUI [4]
C0221130
measurable disease by recist criteria
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
ability to provide written informed consent in accordance with federal, local, and institutional guidelines
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any other current or previous malignancy
Description

Cancer Other

Data type

boolean

Alias
UMLS CUI [1]
C1707251
chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 days
Description

Chemotherapy | Therapeutic radiology procedure | Hormone Therapy | Immunotherapy | Biological treatment | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
UMLS CUI [3]
C0279025
UMLS CUI [4]
C0021083
UMLS CUI [5]
C1531518
UMLS CUI [6]
C0013230
unable to receive medications oral medications
Description

Oral medication Receive Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0175795
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C1299582
major surgery within 28 days before cycle 1 day 1
Description

Major surgery

Data type

boolean

Alias
UMLS CUI [1]
C0679637
active infection requiring within 2 weeks prior to first dose of study drug
Description

Communicable Disease Treatment required for

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0332121
patients who have hiv, hepatitis a, b or c or cmv reactivation
Description

HIV Infection | Hepatitis A | Hepatitis B | Hepatitis C | Cytomegalovirus Infection Reactivation

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019159
UMLS CUI [3]
C0019163
UMLS CUI [4]
C0019196
UMLS CUI [5,1]
C0010823
UMLS CUI [5,2]
C4086768
significant neurotoxicity/neuropathy (grade 3 or higher) within 14 days of first dose of study drug
Description

Neurotoxicity CTCAE Grades | Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0235032
UMLS CUI [1,2]
C1516728
UMLS CUI [2,1]
C0442874
UMLS CUI [2,2]
C1516728
conditions that could interfere with treatment or protocol-related procedures
Description

Condition Interferes with Therapy | Condition Interferes with Interventional procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0087111
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0184661

Similar models

Eligibility Solid Tumors NCT02071862

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Malignant Neoplasms Advanced Recurrent | Malignant Neoplasms Advanced Unresponsive to Treatment | Therapy All Benefit | Patients Standard therapy Refused
Item
advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. newly diagnosed patients who refuse standard treatment regimens are also eligible
boolean
C0006826 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0006826 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0444868 (UMLS CUI [3,2])
C0814225 (UMLS CUI [3,3])
C0030705 (UMLS CUI [4,1])
C2936643 (UMLS CUI [4,2])
C1705116 (UMLS CUI [4,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0-1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1])
Liver function | Renal function | Cardiac function | Hematologic function
Item
adequate hepatic, renal, cardiac, and hematologic function
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232164 (UMLS CUI [3])
C0221130 (UMLS CUI [4])
Measurable Disease
Item
measurable disease by recist criteria
boolean
C1513041 (UMLS CUI [1])
Informed Consent
Item
ability to provide written informed consent in accordance with federal, local, and institutional guidelines
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cancer Other
Item
any other current or previous malignancy
boolean
C1707251 (UMLS CUI [1])
Chemotherapy | Therapeutic radiology procedure | Hormone Therapy | Immunotherapy | Biological treatment | Investigational New Drugs
Item
chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 days
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0279025 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C1531518 (UMLS CUI [5])
C0013230 (UMLS CUI [6])
Oral medication Receive Unable
Item
unable to receive medications oral medications
boolean
C0175795 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Major surgery
Item
major surgery within 28 days before cycle 1 day 1
boolean
C0679637 (UMLS CUI [1])
Communicable Disease Treatment required for
Item
active infection requiring within 2 weeks prior to first dose of study drug
boolean
C0009450 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
HIV Infection | Hepatitis A | Hepatitis B | Hepatitis C | Cytomegalovirus Infection Reactivation
Item
patients who have hiv, hepatitis a, b or c or cmv reactivation
boolean
C0019693 (UMLS CUI [1])
C0019159 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019196 (UMLS CUI [4])
C0010823 (UMLS CUI [5,1])
C4086768 (UMLS CUI [5,2])
Neurotoxicity CTCAE Grades | Neuropathy CTCAE Grades
Item
significant neurotoxicity/neuropathy (grade 3 or higher) within 14 days of first dose of study drug
boolean
C0235032 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0442874 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
Condition Interferes with Therapy | Condition Interferes with Interventional procedure
Item
conditions that could interfere with treatment or protocol-related procedures
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0184661 (UMLS CUI [2,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial